InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: None

Thursday, 12/18/2014 10:16:55 AM

Thursday, December 18, 2014 10:16:55 AM

Post# of 16885
Kinda wish someone from Titan/Braeburn had been at this conference:

https://prevention.nih.gov/programs-events/pathways-to-prevention/workshops/opioids-chronic-pain/workshop-resources


Back in the day, the NIH funded part of propubuphine's development for the opioid abuse indication, and because probuphine eliminates many of the risks mentioned at the conference (accidental overdose, addiction, street resale of medication, lack of knowledge/training by prescribing doctor etc), it would have seemed to be a natural add-on.

The conference materials appear to have been prepared with a definite anti-opioid medication slant to them, but interesting the draft report also reflects testimony of many chronic pain sufferers who states opioids provided them their only hope of living a normal life. It appears what they ended up saying was that opioid prescriptions for chronic pain should be reduced, but not ended entirely, and that controls against abuse should be put into effect...segue to probuphine?

With a market size of 44 million, I wonder what the "off-label" sales potential of probuphine would be? I know suboxone has had substantial off label sales for pain.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News